Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma - Chinatsu Nishioka; Yuki Tahata; Kazuki Maesaka; Machiko Kai; Kumiko Shirai; Kazuhiro Murai; Yuki Makino; Yoshinobu Saito; Yasutoshi Nozaki; Tasuku Nakabori; Hisashi Ishida; Takayuki Yakushijin; et al. (PLoS ONE, 2026)